Abstracts tagged "Spondylarthropathies"

Abstract Number: 2018 • ACR Convergence 2020
Development and Validation of an Artificial Intelligence Approach for the Detection of Radiographic Sacroiliitis
Keno-Kyrill Bressem¹, Janis Vahldiek¹, Lisa Adams¹, Stefan Niehues¹, Hildrun Haibel¹, Valeria Rios Rodriguez¹, Murat Torgutalp¹, Mikhail Protopopov¹, Fabian Proft¹, Judith Rademacher¹, Joachim Sieper¹, Martin Rudwaleit², Bernd Hamm¹, Markus Makowski¹, Kay-Geert Hermann¹ and Denis Poddubnyy³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany, ³Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Conventional radiography of the sacroiliac joints is still recommended as the first imaging method if axial spondyloarthritis (axSpA) is suspected. Furthermore, radiographic sacroiliitis is…
Abstract Number: 1303 • ACR Convergence 2020
Performance of Three Referral Algorithms for Diagnosing Axial Spondyloarthritis: Results from the Screening in Axial Spondyloarthritis for Psoriasis, Iritis, and Colitis Cohort
Ulrich Weber¹, Raj Carmona², James Yeung³, Jon Chan⁴, Liam Martin⁵, Ariel Masetto⁶, Stephanie Keeling⁷, Olga Ziouzina⁵, Sherry Rohekar⁸, Rana Dadashova⁹, Joel Paschke⁹, Amanda Carapellucci⁹, Robert G Lambert¹⁰, Walter Maksymowych⁷ and Sibel Aydin¹¹, ¹University of South Denmark, Odense, Denmark, ²St. Joseph's Healthcare, Hamilton, ON, Canada, ³James Yeung Rheumatology, Vancouver, BC, Canada, ⁴Artus Health Clinic, Vancouver, BC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶University of Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Lawson Health Research Institute, London, ON, Canada, ⁹CARE Arthritis, Edmonton, AB, Canada, ¹⁰University of Alberta and CARE Arthritis, Edmonton, AB, Canada, ¹¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada
Background/Purpose: Patients presenting with back pain and psoriasis, acute anterior uveitis (AAU), or inflammatory bowel disease (IBD), represent a high-risk population for the presence of…
Abstract Number: 1521 • ACR Convergence 2020
A Novel Gut-joint Migratory TCRab+ Cell Subset Relies on sphingosine-1-phosphate for Tissue Localization
Adam Lefferts¹, Emilie Regner², Eric Norman³, David Claypool⁴, Hannah Schultz⁴, Danielle Sansone-Poe⁴ and Kristine Kuhn⁵, ¹University of Colorado, Anschutz Medical Campus, Aurora, CO, ²University of California San Francisco, San Francisco, CA, ³University of Colorado, Anschutz Medical Campus, Denver, ⁴University of Colorado, Anschutz Medical Campus, Aurora, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Despite findings of similar immune cellular phenotypes in the gut and joint of patients with spondyloarthritis, the mechanistic linkage between intestinal immunology and the…
Abstract Number: 2025 • ACR Convergence 2020
Efficacy of Guselkumab, a Monoclonal Antibody That Specifically Binds to the p19 Subunit of IL-23, on Axial-Related Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-52 Results from Two Phase 3, Randomized, Double-blind, Placebo-controlled Studies
Philip Mease¹, Philip Helliwell², Dafna Gladman³, Denis Poddubnyy⁴, Xenofon Baraliakos⁵, Soumya Chakravarty⁶, Alexa Kollmeier⁷, Elizabeth Hsia⁸, Xie Xu⁹, Shihong Sheng¹⁰, Prasheen Agarwal¹⁰, Bei Zhou¹⁰, May Shawi¹¹, Chetan Karyekar¹², Kristen Sweet¹⁰, Atul Deodhar¹³ and Désirée van der Heijde¹⁴, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁹Janssen Research & Development, LLC, San Marcos, CA, ¹⁰Janssen Research & Development, LLC, Spring House, PA, ¹¹Janssen Global Services, LLC, Toronto, ON, Canada, ¹²Janssen Global Services, LLC, Horsham, PA, ¹³Oregon Health & Science University, Portland, OR, ¹⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Guselkumab (GUS), an interleukin-23 inhibitor, improved axial symptoms of active psoriatic arthritis (PsA) through week 24 in a pooled analysis from two phase 3…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].